METHOD FOR SELECTING TARGETED THERAPY IN CHRONIC T2-INFLAMMATORY DISEASES OF NASAL CAVITY AND PARANASAL SINUSES Russian patent published in 2024 - IPC A61K39/395 A61P29/00 A61P37/08 

FIELD: medicine; otorhinolaryngology.

SUBSTANCE: invention can be used for selection of targeted therapy in chronic T2-inflammatory diseases of nasal cavity and paranasal sinuses. Based on the clinical and allergic examination data of the patient, a phenotype of chronic inflammatory diseases of the nose and paranasal sinuses is identified: allergic—the absence of chronic rhinosinusitis, presence of eosinophils in complete blood count (CBC), positive allergy history and allergological tests; mixed phenotype—the presence of chronic rhinosinusitis with or without polyps, the number of eosinophils in the CBC≥250 cells/mcl, positive allergic anamnesis and allergological tests and eosinophilic phenotype—presence of chronic rhinosinusitis with polyps or without, number of eosinophils in CBC≥250 cells/mcl, negative allergic anamnesis and allergological tests. In case of allergic phenotype, anti-IgE-therapy is chosen, in case of mixed phenotype—anti-IL4/IL13-therapy, in case of eosinophilic phenotype—anti-IL5-therapy.

EFFECT: method provides a personalized selection of the targeted therapy in chronic T2-inflammatory diseases of the nasal cavity and paranasal sinuses by isolating the patient’s phenotype based on clinical and allergic examination data.

1 cl, 1 dwg, 4 tbl, 3 ex